Profluent closed a $106 million financing led by Altimeter Capital and Bezos Expeditions to expand its large‑scale AI models for protein design and commercialize across therapeutics, agriculture and biomanufacturing. The company highlighted its Protein Atlas — a database of over 115 billion proteins — and cited partnerships with IDT and Revvity as early commercial traction points. Profluent’s raise underscores continued investor appetite for AI-native biotech platforms that promise to compress design cycles and produce bespoke enzymes, antibodies, and other biologics. The funding will expand platform capabilities and accelerate partnerships aimed at moving designs toward experimental validation and commercialization. Investors and industry partners will watch how Profluent translates model outputs into reproducible, clinic‑ready molecules and whether its platform lowers the cost and time barriers for advanced biologic engineering.